Research and Markets (http://www.researchandmarkets.com/research/e70b48/the_future_of_the) has announced the addition of the "The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles" report to their offering.
The major contemporary bioterrorist event which has opened up programs of research and development (R&D) in pharmaceutical countermeasures and treatments was the anthrax mail attacks which occurred only weeks after the 9/11 atrocities, in October 2001. The mailings killed five people and exposed hundreds more - with thousands of US citizens seeking prophylactic antibiotics. Since then the biodefense industry has grown massively, with the US releasing around $50bn in biodefence funding in 2001-2009. Other international bodies, such as the EU, have also increased their vigilance and research efforts.
This report sets out to describe and analyze the work of the biodefense industry in terms of past, present and future pharmaceutical research, development and production to counter or treat diseases caused by biological attack. It also will describe government policies and initiatives in several countries which have spurred research and production in pharmaceutical countermeasures and treatments for such diseases and will examine the various factors which influence those policies and the market, including current and future threats and how the industry is responding to new discoveries.
Scope of this report
- Analysis of government funding levels in the US and Europe and information on current grants available for biodefense research.
- Estimation of biodefense in the US for 2010 and forecast figures to 2012.
- In-depth analysis of the major biodefense firms operating in the US, Europe, Australia and Canada as well as well as those operating in emerging markets such as China, India and Israel.
- Analysis of the major threat areas in the biodefense market including - anthrax, plague, tularemia, small pox viral hemorrhagic fevers, botulism, ricin, staphylococcal enterotoxins, brucella, glanders, melioidosis and Q fever.
Key findings from this report
- The US is driving the industry and total biodefense funding between 2001-2009 reached $49.6bn. However, growth is set to slow significantly in the coming years as all Project BioShield funding has now released.
- However, a single serious bioterrorist incident in the US could spur another round of government spending as happened after the 2001 anthrax attacks. Recent threats such as pandemic swine flu are also forcing governments to consider the creation of large stockpiles of medical countermeasure.
- The current economic crisis could be especially serious for the biodefense industry. As many of the active participants are small-scale and reliant on outside funding to maintain operations, reduced credit options could force them out of business
Key issues